Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management (Q33975071)

30 July 2017

1 reference

title

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management (English)

1 reference

30 July 2017

1 reference

Jeffrey Crawford

1

1 reference

30 July 2017

David C Dale

series ordinal

2

1 reference

30 July 2017

Gary H Lyman

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

30 July 2017

1 reference

30 July 2017

100

1 reference

30 July 2017

2

1 reference

30 July 2017

228-237

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Management of cancer in the older person: a practical approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Science and pragmatism in the treatment and prevention of neutropenic infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

New trends in patient management: risk-based therapy for febrile patients with neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Filgrastim in patients with neutropenia: potential effects on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11882

7 January 2021

Identifiers

DOI

10.1002/CNCR.11882

1 reference

30 July 2017

1 reference